title: Could the efficacy of docetaxel in prostate cancer patients be potentiated by concomitant high-dose calcitriol administration?
authors.forename: Alfredo
authors.initials: A
authors.lastname: Berruti
authors.forename: Marcello
authors.initials: M
authors.lastname: Tucci
authors.forename: Alessandra
authors.initials: A
authors.lastname: Mosca
authors.forename: Mara
authors.initials: M
authors.lastname: Ardine
authors.forename: Massimiliano
authors.initials: M
authors.lastname: Poggio
authors.forename: Andrea
authors.initials: A
authors.lastname: Saini
authors.forename: Lucianna
authors.initials: L
authors.lastname: Russo
authors.forename: Federica
authors.initials: F
authors.lastname: Vana
authors.forename: Luigi
authors.initials: L
authors.lastname: Dogliotti
mesh_terms: D000970:Antineoplastic Agents / Q000008:administration & dosage; D050071:Bone Density Conservation Agents / Q000008:administration & dosage*; D001859:Bone Neoplasms / Q000150:complications / Q000556:secondary; D002117:Calcitriol / Q000008:administration & dosage*; D002986:Clinical Trials as Topic; D000077143:Docetaxel; D004357:Drug Synergism; D006801:Humans; D006996:Hypocalcemia / Q000209:etiology / Q000517:prevention & control; D008297:Male; D011471:Prostatic Neoplasms / Q000188:drug therapy*; D043823:Taxoids / Q000008:administration & dosage*
chemical_list: D000970:Antineoplastic Agents; D050071:Bone Density Conservation Agents; D043823:Taxoids; D000077143:Docetaxel; D002117:Calcitriol